한글목차

골다공증은 시간이 지남에 따라 뼈의 밀도와 질이 감소하는 질환입니다. 리모델링으로 알려진 정상적인 과정에서 사람의 뼈 세포의 일부가 용해(흡수)되고 새로운 뼈 세포가 다시 성장합니다. 골다공증 환자는 뼈의 감소가 새로운 뼈의 성장을 능가합니다. 그 결과 뼈가 다공성이고 부서지기 쉬워 골격이 약해져 고관절, 척추 및 손목 골절의 위험이 증가합니다. 골다공증은 종종 "침묵의 질병"이라고 불리는데, 그 이유는 골량 감소가 진행되어 첫 번째 골절이 발생할 때까지 자각 증상이 나타나지 않는 경우가 많기 때문입니다. 뼈가 매우 약해지고 부서지기 쉬워지기 때문에 넘어지거나 허리를 숙이거나 기침을 하는 등 가벼운 스트레스에도 골절이 발생할 수 있습니다. 전 세계적으로 여성 3명 중 1명, 남성 5명 중 1명이 골다공증성 골절의 위험에 노출되어 있으며, 골다공증성 골절에 따른 이환율과 사망률로 볼 때 골다공증은 심혈관 질환에 이어 두 번째로 큰 세계 건강 부담이 되고 있습니다.

세계 주요 7개국에서 골다공증 환자 수는 2023년 51,169,521명에서 2033년 58,050,255명으로 증가해 연간 성장률(AGR)이 1.34%에 달할 것으로 예측됐습니다. 주요 7개국에서 골다공증 진단을 받은 환자 수는 2023년 20,291,551명에서 2033년 22,570,292명으로 증가해 1.12%의 AGR을 기록할 것으로 예상됩니다. 예측 기간 동안 모든 시장에서 골다공증 총 유병률과 진단받은 환자 수가 증가할 것으로 예상됩니다.

이 보고서는 주요 7개국 시장의 골다공증 위험인자, 동반질환, 세계 및 과거 역학 동향을 개괄하고, 골다공증 진단 사례와 진단된 유병률에 대한 10년간의 역학 전망 등을 정리했습니다.

목차

제1장 골다공증 : 주요 요약

제2장 역학

• 질병 배경
• 위험인자와 합병증
• 세계적 및 과거적 동향
• 주요 7개국 예측 조사 방법
• 골다공증 역학 예측(2023-2033년)
  • 골다공증 총이환수
  • 골다공증 총이환 증례수, 연령별
  • 골다공증 이환율, 성별
  • 원발성 골다공증과 이차성 골다공증별 골다공증 총이환수
  • 원발성 골다공증 이환 증례수, 유형별
  • 글루코코르티코이드 사용에 기인하는 골다공증 총이환 증례수
  • 골다공증 진단 환자
  • 진단된 골다공증 유병률, 연령별
  • 골다공증 유병률, 성별
  • 원발성 골다공증과 이차성 골다공증 진단 환자
  • 원발성 골다공증 진단 환자, 유형별
  • 글루코코르티코이드 사용에 기인하는 골다공증 진단 환자
• 논의
  • 역학 예측 인사이트
  • COVID-19의 영향
  • 분석의 한계
  • 분석의 강점

제3장 부록

영문목차

Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person's bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a "silent" disease because the loss of bone occurs progressively and often there are no symptoms until the first fracture occurs (SCOPE, 2021). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture (Mayo Clinic, 2024). Around the world, one in three women and one in five men are at risk of an osteoporotic fracture (SCOPE, 2021). The morbidity and mortality associated with osteoporotic fractures make osteoporosis a global health burden second only to cardiovascular disease (Kanis et al., 1997; Pisani et al., 2016). As the world's population ages, the global burden of the disease is expected to increase.

In the 7MM, the total prevalent cases of osteoporosis will increase from 51,169,521 cases in 2023 to 58,050,255 cases in 2033, at an annual growth rate (AGR) of 1.34%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 20,291,551 cases in 2023 to 22,570,292 cases in 2033, at an AGR of 1.12%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age (ages 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, and total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, the total and diagnosed prevalent cases of type 2 (age-associated/senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
• To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

Reasons to Buy

The Osteoporosis epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global MM market.
• Quantify patient populations in the global Osteoporosis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Osteoporosis therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData
• List of Contents

List of Tables

List of Figures

1 Osteoporosis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: total prevalent cases of osteoporosis
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of osteoporosis
  • 2.4.5 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of primary osteoporosis and secondary osteoporosis
  • 2.4.6 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of type 1 and type 2 osteoporosis
  • 2.4.7 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use
  • 2.4.8 Forecast assumptions and methods: total prevalent cases of osteopenia
  • 2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of osteopenia
• 2.5 Epidemiological forecast for osteoporosis (2023-33)
  • 2.5.1 Total prevalent cases of osteoporosis
  • 2.5.2 Age-specific total prevalent cases of osteoporosis
  • 2.5.3 Sex-specific total prevalent cases of osteoporosis
  • 2.5.4 Total prevalent cases of osteoporosis by primary and secondary osteoporosis
  • 2.5.5 Total prevalent cases of primary osteoporosis by type
  • 2.5.6 Total prevalent cases of osteoporosis secondary to glucocorticoid use
  • 2.5.7 Diagnosed prevalent cases of osteoporosis
  • 2.5.8 Age-specific diagnosed prevalent cases of osteoporosis
  • 2.5.9 Sex-specific diagnosed prevalent cases of osteoporosis
  • 2.5.10 Diagnosed prevalent cases of osteoporosis by primary and secondary osteoporosis
  • 2.5.11 Diagnosed prevalent cases of primary osteoporosis by type
  • 2.5.12 Diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
• Contact Us